COGNITION THERAPEUTICS INC (CGTX) Fundamental Analysis & Valuation

NASDAQ:CGTX • US19243B1026

1.02 USD
-0.04 (-3.77%)
At close: Mar 3, 2026
1.03 USD
+0.01 (+0.98%)
Pre-Market: 3/4/2026, 4:02:02 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CGTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

CGTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. CGTX has a great financial health rating, but its profitability evaluates not so good. CGTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. CGTX Profitability Analysis

1.1 Basic Checks

  • CGTX had negative earnings in the past year.
  • In the past year CGTX has reported a negative cash flow from operations.
  • In the past 5 years CGTX always reported negative net income.
  • In the past 5 years CGTX always reported negative operating cash flow.
CGTX Yearly Net Income VS EBIT VS OCF VS FCFCGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • CGTX has a Return On Assets of -64.49%. This is in the lower half of the industry: CGTX underperforms 68.39% of its industry peers.
  • CGTX has a Return On Equity (-76.61%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -64.49%
ROE -76.61%
ROIC N/A
ROA(3y)-76.04%
ROA(5y)-85.03%
ROE(3y)-113.24%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGTX Yearly ROA, ROE, ROICCGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

  • CGTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGTX Yearly Profit, Operating, Gross MarginsCGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CGTX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CGTX has more shares outstanding
  • The number of shares outstanding for CGTX has been increased compared to 5 years ago.
  • There is no outstanding debt for CGTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGTX Yearly Shares OutstandingCGTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CGTX Yearly Total Debt VS Total AssetsCGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -0.84, we must say that CGTX is in the distress zone and has some risk of bankruptcy.
  • CGTX's Altman-Z score of -0.84 is in line compared to the rest of the industry. CGTX outperforms 48.19% of its industry peers.
  • There is no outstanding debt for CGTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.84
ROIC/WACCN/A
WACCN/A
CGTX Yearly LT Debt VS Equity VS FCFCGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 6.44 indicates that CGTX has no problem at all paying its short term obligations.
  • CGTX has a Current ratio of 6.44. This is in the better half of the industry: CGTX outperforms 69.95% of its industry peers.
  • CGTX has a Quick Ratio of 6.44. This indicates that CGTX is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 6.44, CGTX is doing good in the industry, outperforming 70.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.44
Quick Ratio 6.44
CGTX Yearly Current Assets VS Current LiabilitesCGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CGTX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 50.52% over the past year.
EPS 1Y (TTM)50.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CGTX will show a small growth in Earnings Per Share. The EPS will grow by 6.27% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.71%
EPS Next 2Y29.52%
EPS Next 3Y14.37%
EPS Next 5Y6.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CGTX Yearly Revenue VS EstimatesCGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M
CGTX Yearly EPS VS EstimatesCGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 0.5 -0.5 1 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. CGTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CGTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGTX Price Earnings VS Forward Price EarningsCGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGTX Per share dataCGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

  • CGTX's earnings are expected to grow with 14.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.52%
EPS Next 3Y14.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CGTX Dividend Analysis

5.1 Amount

  • No dividends for CGTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CGTX Fundamentals: All Metrics, Ratios and Statistics

COGNITION THERAPEUTICS INC

NASDAQ:CGTX (3/3/2026, 8:01:10 PM)

Premarket: 1.03 +0.01 (+0.98%)

1.02

-0.04 (-3.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-18
Inst Owners24.17%
Inst Owner Change9.34%
Ins Owners0.83%
Ins Owner Change17.83%
Market Cap90.04M
Revenue(TTM)N/A
Net Income(TTM)-27.99M
Analysts82
Price Target3.57 (250%)
Short Float %8.55%
Short Ratio8.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.04%
Min EPS beat(2)-1.1%
Max EPS beat(2)41.18%
EPS beat(4)1
Avg EPS beat(4)-0.45%
Min EPS beat(4)-24.49%
Max EPS beat(4)41.18%
EPS beat(8)3
Avg EPS beat(8)3.72%
EPS beat(12)6
Avg EPS beat(12)4.22%
EPS beat(16)9
Avg EPS beat(16)-262.07%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.41%
EPS NY rev (1m)0%
EPS NY rev (3m)3.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.46
P/tB 2.46
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.49%
ROE -76.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.04%
ROA(5y)-85.03%
ROE(3y)-113.24%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -1.52%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.44
Quick Ratio 6.44
Altman-Z -0.84
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)123.12%
Cap/Depr(5y)82.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
EPS Next Y52.71%
EPS Next 2Y29.52%
EPS Next 3Y14.37%
EPS Next 5Y6.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.4%
OCF growth 3YN/A
OCF growth 5YN/A

COGNITION THERAPEUTICS INC / CGTX FAQ

What is the fundamental rating for CGTX stock?

ChartMill assigns a fundamental rating of 2 / 10 to CGTX.


Can you provide the valuation status for COGNITION THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to COGNITION THERAPEUTICS INC (CGTX). This can be considered as Overvalued.


Can you provide the profitability details for COGNITION THERAPEUTICS INC?

COGNITION THERAPEUTICS INC (CGTX) has a profitability rating of 0 / 10.